Dapagliflozin Effect on Cardiovascular Outcomes in Haemodialysis for End Stage Renal Disease
Status:
Withdrawn
Trial end date:
2026-06-01
Target enrollment:
Participant gender:
Summary
This study aims to study SGLT2 inhibitors in patients who are undergoing haemodialysis for
end stage renal disease and established ASCVD, to examine the safety and clinical outcomes,
consisting of a composite of non-fatal stroke, non-fatal myocardial infarction, or
cardiovascular death as the primary outcome. The key secondary composite outcome was all
cause death or hospitalization for unstable angina.